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ABSTRACT
Greater understanding of the underlying etiology and
biology of breast cancer is enabling the clinical develop-
ment of targeted therapies for metastatic breast cancer
(MBC). Following the successful introduction of trastu-
zumab, the first human epidermal growth factor recep-
tor (HER) biologically targeted therapy to become
widelyusedinMBCpatients,otheragentshavebeende-
veloped. Novel agents include monoclonal antibodies
such as pertuzumab, which bind to receptors on the cell
surface, and tyrosine kinase inhibitors (TKIs) such as
lapatinib, which target intracellular pathways such as
that of the epidermal growth factor receptor. There is
also growing clinical experience with antiangiogenic
agents,particularlyincombinationwithchemotherapy.
These include the monoclonal antibody bevacizumab,
which targets vascular endothelial growth factor recep-
tor, and multitargeted TKIs with antiangiogenic and
antiproliferative activities, such as sunitinib. Combina-
tion treatment with multiple agents targeting both the
HER family and angiogenic pathways (e.g., trastu-
zumab plus bevacizumab) is also showing activity in the
clinical setting. Despite recent advances, there are un-
answeredquestionsregardingthemanagementofMBC
withtargetedagents.Futurestudiesarenecessarytode-
termine the optimal combinations, doses, and schedules
required to maximize clinical activity while minimizing
toxicity. Despite the temptation to use a targeted agent
in all patients, identification of patient subgroups most
likely to benefit must be a key goal and will be critical to
the successful future use of these treatments. The aim of
this review is to summarize some of the key signaling
pathways involved in tumor progression and some of
the novel therapies that are in development for MBC.
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INTRODUCTION
Themechanismsunderlyingthedevelopmentofbreastcan-
cer are complex and vary among individual tumors [1].
Theseincludegeneticandepigeneticalterations,andresult-
ing changes in the activity of signaling pathways.
Mutationsorepigeneticfunctionalinactivationoftumor
suppressor genes may contribute to the early development
of some tumors, and alterations in proto-oncogenes may
alsobeinvolved[2].Alteredpatternsofgeneexpressionare
associated with corresponding variations in growth rates
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gene expression can help to define tumor subtypes. Two of
thesubtypessofaridentifiedarethosewithgeneexpression
characteristics typical of basal epithelial cells (which are
predominantly estrogen receptor [ER]
) and those with
geneexpressioncharacteristicstypicalofluminalepithelial
cells (which are predominantly ER
) [3, 4]. Different pat-
terns of gene expression are also associated with differing
prognoses, and genetic assay techniques are increasingly
being used to provide information on outcome, including
the risk for tumor recurrence and whether an individual is
likely to benefit from a particular chemotherapy [5]. Typi-
cally, tumors of the ER
, basal subtype are associated with
shorter relapse-free and overall survival times than those of
the ER
, luminal subtype [4]. Altered patterns of gene ex-
pressioncanalsoinfluencetheactivityofspecificsignaling
pathways. Variations in the pathways associated with the
human epidermal growth factor receptor (HER) family,
which are encoded by genes on different chromosomes and
regulate normal breast growth and development, appear to
be particularly important, not only in tumor development
but also in treatment efficacy [6, 7]. Given the complex and
varied factors that influence the development of breast can-
cer, and the use of increasingly sophisticated genetic anal-
ysistechniques,itislikelythatmorerefinedtumorsubtypes
and their associated prognoses will be identified [1, 8].
Currenttreatmentstrategiesformetastaticbreastcancer
(MBC) depend upon patient and tumor classification;
menopausal status, hormone receptor status, and HER-2
status may all be considered, as may site of metastatic dis-
ease (bone or soft tissue). The choice of treatment in meta-
staticdiseaseisstillamatterofdebate,butusuallyinvolves
systemic endocrine therapy or cytotoxic chemotherapy,
with an anti–HER-2 agent when appropriate. Novel agents
are needed because many of the current therapies have lim-
itations.Theseincludedrugresistance,lackoftargetrecep-
tor expression in tumors (e.g., only 25% of breast cancer
tumors have HER-2 expression), and relatively small im-
provements in survival [9–12]. In addition, as more treat-
mentoptionsbecomeavailableinthefirst-lineandadjuvant
settings, there is less clarity about choices for patients with
metastatic or refractory disease. Advances in the under-
standing of the etiology and biology of breast cancer have
identified key targets among the multiple signaling path-
ways involved in the development, growth, and survival of
breast cancer cells (Fig. 1). As such, targeted therapies are
among the most promising new agents for the treatment of
breast cancer.
This review focuses on some of the mechanisms and
pathwaysinfluencingtumorcellproliferation,survival,and
invasiveness that are being exploited to develop novel ther-
apiesforthetreatmentofMBC.Targetscurrentlyidentified
Figure 1. Key targets for breast cancer treatment.
Abbreviations: DAG, diacyl glycerol; EGFR, epidermal growth factor receptor; ERK, extracellular signal–related kinase ki-
nase; HER-2, human epidermal growth factor receptor 2; IP3, inositol 1,4,5-trisphosphate; mTOR, mammalian target of rapamy-
cin; PDGFR-, platelet-derived growth factor receptor ; PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol 4,5-
bisphosphate; PKC, protein kinase C; VEGFR, vascular endothelial growth factor receptor.
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activated protein kinase (MAPK), phosphatidylinositol
3-kinase(PI3K),andapoptoticsignalingpathways.Factors
modulating angiogenesis are additional targets for therapy,
and recent clinical developments with antiangiogenic ther-
apies are also reviewed. There appears to be extensive
crosstalk between the pathways driving tumorigenic pro-
cesses, and this provides a good rationale for inhibiting
multiplepathwaysandprocesseswithmultitargetedagents,
either as single agents or in combination.
THE HER FAMILY
TheHERfamilyconsistsoffourcloselyrelatedtyrosineki-
nase receptors: HER-1 (also termed epidermal growth fac-
tor receptor [EGFR] or ErbB-1), HER-2 (also termed
ErbB-2 or HER-2/neu), HER-3 (ErbB-3), and HER-4
(ErbB-4) [13]. Through their interconnected cellular sig-
naling network, the HER family regulates diverse biologi-
cal processes, including cell proliferation, differentiation,
and survival [13, 14], and plays a key role in the develop-
ment and progression of breast cancer [13, 15, 16]. Expres-
sion of HER family members in breast cancer tumors has a
significant impact on tumor aggressiveness and patient sur-
vival. HER-1 and HER-2 are expressed in approximately
16%–48% and 25%–30% of breast cancer tumors, respec-
tively, and their expression correlates with a more aggres-
sive disease course, shorter survival time, and higher risk
for resistance to endocrine therapies [9, 10, 17–23]. HER-3
expression, observed in approximately 18% of tumors, also
correlates with shorter overall survival [19]. Interestingly,
expression of HER-4 (found in approximately 12% of tu-
mors) has been associated with more favorable tumor char-
acteristics and longer survival [18, 19].
Each HER receptor has an extracellular domain in-
volvedinligandbinding,ahelicaltransmembranesegment,
and an intracellular protein tyrosine kinase domain [13, 24]
Figure 2. HER-activated signaling pathways.
Abbreviations: BAD, Bcl-2-associated death promoter; EGFR, epidermal growth factor receptor; GSK3, glycogen synthase
kinase 3; HER-2, human epidermal growth factor receptor 2; HIF-1, hypoxia inducible factor 1; MAPK, mitogen-activated
protein kinase; MDM2, murine double minute 2; mTOR, mammalian target of rapamycin; PI3K, phosphatidylinositol 3-kinase;
PKC, protein kinase C; PLC, phospholipase C. Adapted from Atalay G, Cardoso F, Awada A et al. Novel therapeutic strategies
targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol 2003;
14:1346–1363, by permission of Oxford University Press.
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receptors undergo conformational changes, which allows
them to form homodimers (consisting of two identical re-
ceptors) or heterodimers (consisting of two different recep-
tors) of the HER family [13, 24] (Fig. 2). More than 10
ligands have so far been identified that bind to HER-1,
HER-3, and HER-4, including epidermal growth factor
(EGF), transforming growth factor , amphiregulin, beta-
cellulin,epiregulin,heparin-bindingEGF,andneuregulin1
through neuregulin 4 [13]. Putative ligands of HER-2 have
beencharacterized,butnospecificligandhasyetbeeniden-
tified [24]. This has clinical implications in terms of there
beingnoalternativeapproachtoblockingthispathway,and
this may be related to the development of resistance to
HER-2 blockade.
The specific receptors involved in each dimer affect the
type and number of downstream effectors activated, and
also influence the downregulation mechanism for the li-
gand-bound receptors [24]. Dimerization of HER receptors
induces phosphorylation of their intracellular tyrosine ki-
nase domains, which provide docking sites for adaptor pro-
teins and signaling enzymes [24]. These molecules act as a
link between membrane receptor kinases and “down-
stream” intracellular protein kinases, which results in the
activation of multiple signaling pathways, of which the
MAPK and PI3K pathways are probably the best under-
stood [24] (Fig. 2). Given the absence of known ligands for
HER-2, and lack of tyrosine kinase activity of HER-3, it is
assumed that these receptors must form heterodimers with
another member of the HER family in order to activate sig-
naling [24]. HER-2 is the preferred dimerization and sig-
nalingpartnerforallothermembersoftheHERfamily,and
it appears to function mainly as a coreceptor, increasing the
affinity of ligand binding to dimerized receptor complexes
[24, 25]. With their multiple ligands, many dimerization
combinations, and large number of downstream effec-
tors, the HER family mediates an extensive range of
signals, controlling a variety of cellular processes, in-
cluding cellular proliferation, apoptosis, and angiogene-
sis [24, 26] (Fig. 2).
Targeted Therapies Directed at the HER Family
of Receptors
NumerousagentstargetingindividualmembersoftheHER
family have been developed for use in the treatment of
breastcancer.Table1summarizesthosethatarelicensedor
in phase III clinical development. Existing therapeutic ap-
proacheshavelargelyfocusedontwoclassesofagents.The
firstcomprisesmonoclonalantibodiesthatbindtoextracel-
lular regions of HER to interfere with receptor function
(e.g., trastuzumab, pertuzumab, and a number of pan-HER
inhibitors). Trastuzumab binds to the juxtamembrane re-
gion of HER-2 with high specificity, but it is not currently
known how it specifically interferes with HER-2 function
[27]. Pertuzumab is the first in a class of HER-2 dimeriza-
tion inhibitors. Binding to HER-2 inhibits its dimerization
with other HER receptors and this is thought to result in
slowed tumor growth [28]. The second class of HER-tar-
geted agents comprises the small molecule tyrosine kinase
inhibitors(TKIs)thatinhibitenzymefunctionofHERfam-
ily members intracellularly. Oral TKIs include lapatinib, ne-
ratinib (both inhibit HER-1 and HER-2), erlotinib and
gefitinibthattargettheintracellulardomainofHER-1,andthe
irreversible pan-HER inhibitors PF-00299804 and canertinib,
which inhibit the kinase signaling of multiple HER family
members [29, 30].
Extracellular Targeted Therapies:
Monoclonal Antibodies
Trastuzumab. Trastuzumab, administered as an i.v. infu-
sion,isapprovedintheU.S.andEuropeforthetreatmentof
HER-2–overexpressing MBC [31]. It is standard-of-care
treatment for MBC patients with HER-2–overexpressing
tumors, both as first-line treatment in combination with
chemotherapy and as a single agent in women who have
HER-2–overexpressing MBC that has progressed after
chemotherapy for metastatic disease [32, 33]. Trastuzumab
is approved for the adjuvant treatment of HER-2
, node-
negative (ER
/progesterone receptor [PgR]
 or with one
high-risk feature) or node-positive breast cancer, either in
combinationwithchemotherapyorasasingleagentfollow-
ing multimodality anthracycline-based treatment.
Studieshaveevaluatedarangeofdifferenttrastuzumab-
based combination regimens for the first-line treatment of
MBC (Table 2A) [34–48]. Additionally, a number of trials
are ongoing investigating trastuzumab in combination with
hormonal therapy in MBC patients [49, 50].
When administered as a single agent, trastuzumab has
documented efficacy as a first-line therapy, with response
ratestypicallyintherangeof23%–33%[51–53].However,
no benefit has been observed treating patients with single-
agent trastuzumab followed by chemotherapy with or with-
out trastuzumab on progression [35, 41]. Of those patients
with MBC who do achieve an initial response, many expe-
rience disease progression within 12 months as a result of
the high proportion of HER-2–overexpressing tumors that
haveintrinsicresistancetothisagent[54].However,chang-
ing the traditional treatment paradigm in patients progress-
ing on trastuzumab and administering further trastuzumab-
based therapy beyond disease progression may have
clinical benefit [55, 56]. This “treatment beyond progres-
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als by combining trastuzumab either with chemotherapy
[43, 57, 58] or with another targeted agent, such as the TKI
lapatinib[59,60]andtheHER-2dimerizationinhibitorper-
tuzumab [28, 61] (Table 2B).
A phase III evaluation of continuing trastuzumab and
capecitabine versus capecitabine alone in patients (n 
156) with HER-2
 MBC who had progressed during tras-
tuzumab treatment found that the combination led to a
longer time to progression (TTP), by nearly 3 months, than
withcapecitabinealone(8.2monthsversus5.6months;p
.034) [43]. In addition, recent phase II data showed how
50% of patients who had progressed on trastuzumab ther-
apybenefitedfromcombinationtreatmentwithpertuzumab
and trastuzumab; combination treatment resulted in an
overall response rate (ORR) of 24.2% (complete response
rate, 7.6%; partial response [PR] rate, 16.7%; rate of stable
disease [SD] 6 months, 25.8%) and a progression-free
survival (PFS) duration of 24 weeks [28, 45]. The combi-
nation appeared to be well tolerated, and no patients were
withdrawn as a result of toxicities. A phase III clinical trial
(CLEOPATRA) evaluating trastuzumab plus chemother-
apywithandwithoutpertuzumabforthefirst-linetreatment
of HER-2
 MBC is currently ongoing [45]. Interestingly,
an evaluation of trastuzumab use beyond disease progres-
sion by the National Comprehensive Cancer Network
found that, of the total 165 patient cohort, 46 patients
stopped first-line treatment because of disease progression.
Ofthose46patients,74%continuedtoreceivetrastuzumab
as part of second-line therapy and nine of 46 (19.6%) pa-
tients were treated in a clinical trial [48].
Trastuzumab-DM1 (T-DM1) is an anti–HER-2 anti-
body drug conjugate comprising trastuzumab linked to the
maytansine derivative DM1. Combining these two agents
facilitates anti–HER-2 activity as well as targeted intracel-
lular delivery of a potent cytotoxic agent. Single-agent T-
Table 1. Therapies currently licensed or in phase III clinical development for MBC
Target
pathway Agent Specific target
Drug
class Licensing status
HER Trastuzumab (Herceptin) HER-2 mAb MBC: In combination with paclitaxel for
first-line treatment of HER-2
 patients; as a
single agent for treatment of HER-2

patients who have received one or more
chemotherapy regimens for MBC
Adjuvant: For HER-2–
overexpressing node-positive or node-
negative breast cancer as part of a regimen
consisting of doxorubicin,
cyclophosphamide, and either paclitaxel or
docetaxel; with docetaxel and carboplatin; as
a single agent following multimodality
anthracycline-based therapy
Pertuzumab (Omnitarg) HER-2 mAb Not currently approved in breast cancer
Lapatinib (Tykerb/Tyverb) HER-1 and HER-2 TKI MBC: In combination with capecitabine in
HER-2
 patients who have progressed
following trastuzumab, an anthracycline, and
a taxane (application submitted for first-line
therapy in combination with hormonal
therapy)
Neratinib HER-1 and HER-2 TKI Not currently approved in breast cancer
Angiogenesis Bevacizumab (Avastin) VEGF mAb MBC: In combination with docetaxel (EU) or
paclitaxel (EU and U.S.) for first-line
treatment
Sunitinib malate (SUTENT) VEGFR-1, VEGFR-2,
VEGFR-3, PDGFR-,
PDGFR-, Kit, RET,
FLT-3, CSF-1R
TKI Not currently approved in breast cancer
Many other targeted agents are currently being investigated in early phase I/II clinical trials of MBC (e.g., pazopanib,
axitinib, sorafenib, everolimus).
Abbreviations: CSF-1R, colony-stimulating factor 1 receptor; EU, European Union; FLT-3, FMS-like tyrosine kinase 3;
HER, human epidermal growth factor receptor; mAb, monoclonal antibody; MBC, metastatic breast cancer; PDGFR,
platelet-derived growth factor receptor; RET, glial cell-derived neurotrophic factor (REarranged during Transfection); TKI,
tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.
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222 MBC: Targeting Signal Transduction PathwaysDM1 was well tolerated and active (ORR, 25%; clinical
benefit rate [CBR], 34.8%) and no dose-limiting cardiotox-
icity was observed in a phase II study of 112 patients with
pretreated MBC [62].
Limitations of Trastuzumab Therapy. Trastuzumab is
unable to penetrate the blood–brain barrier [63], and over-
expression of HER-2 is known to be associated with a
greater risk for central nervous system (CNS) metastases
[64]. Patients with HER-2
 MBC treated with trastuzumab
appear to be at greater risk for developing CNS metastases
than those who do not receive trastuzumab therapy [65, 66].
However, HER-2
 patients with CNS metastases who are
treated with trastuzumab appear to have a longer overall sur-
vivaldurationthanthosewhoareHER-2
orthoseunselected
for HER-2 status. This may reflect greater control of extracra-
nial disease as a result of trastuzumab therapy [67].
Treatment with trastuzumab is associated with a higher
riskforcardiomyopathy(leftventriculardysfunctionandcon-
gestive heart failure), particularly when used in combination
with paclitaxel or anthracyclines [68]. However, these cardio-
toxic effects appear to be reversible once trastuzumab treat-
ment is discontinued or if they are managed with appropriate
medical therapy [69, 70]. The cellular mechanisms contribut-
ing to the cardiotoxicity observed with trastuzumab are still
beingexplored.ItisknownthatHER-2playsanimportantrole
in cardiomyocyte development and function, and trastu-
zumab-induced inhibition of HER-2 signaling in cardiomyo-
cytes may be a central mechanism underlying the observed
cardiomyopathy [71]. However, the full explanation is likely
to be more complex. Cardiotoxicity does not appear to be an
issue with the TKI lapatinib, which inhibits both HER-1 and
HER-2 [71]. Although cardiotoxicity is the primary safety
concern with trastuzumab, potentially severe hypersensitivity
reactions to infusion have also been reported [31].
In summary, trastuzumab is an effective treatment for
patients with HER-2
 disease, although its use is limited to
this group (approximately 25%) [20]; accurate patient se-
lection for treatment is important, using an appropriate
method, such as immunohistochemistry or fluorescence in
situ hybridization, to detect HER-2 overexpression. Addi-
tionally, not all HER-2
 patients respond to treatment with
trastuzumab, and the development of resistance is an issue.
In the future, it may be possible to overcome resistance by
combining trastuzumab with new therapies such as pertu-
zumab, by switching to an agent such as lapatinib that in-
hibits both HER-1 and HER-2 activity, or, if proven
effective,theuseofoneofthepan-HERinhibitorscurrently
in development. The efficacy that trastuzumab has demon-
strated in the metastatic setting has provided the rationale
forseveralstudiesinvestigatingtheuseoftrastuzumabplus
chemotherapyasadjuvanttreatmentforpatientswithearly-
stage HER-2
 breast cancer, a key area for development
[72–77]. Cardiotoxicity remains a key safety concern for
the use of trastuzumab, although in most patients this is re-
versible once trastuzumab is discontinued and/or appropri-
ate medical treatment is given [68–70].
Intracellular Targeted Therapies: TKIs
Lapatinib. LapatinibisapprovedintheU.S.(March2007)
and European Union (EU) (June 2008) for use (oral admin-
istration) in combination with capecitabine for the treat-
ment of patients with advanced breast cancer or MBC
whose tumors overexpress HER-2 and who have received
priortherapyincludingananthracycline,ataxane,andtras-
tuzumab [78, 79].
In a pivotal phase III study that provided the basis for
regulatory approval, a combination of lapatinib plus cape-
citabine led to a significantly longer median TTP than with
capecitabine alone (8.4 months versus 4.4 months; p 
.001) in patients with progressive, HER-2
, locally ad-
vanced or MBC refractory to trastuzumab (n  324) [80].
This was a notable finding, in that 97% of the patients had
previously received treatment with trastuzumab and given
that the data were similar to those reported in the phase III
trastuzumab plus capecitabine trial in patients progressing
on trastuzumab (TTP, 8.4 months versus 8.2 months) [43].
The incidences of adverse events (including those leading
to treatment discontinuation) and symptomatic cardiac
events were similar in both treatment groups [80].
Additional studies are ongoing to evaluate lapatinib in
combinationwithtrastuzumab,otherchemotherapyagents,
hormonal therapy, anti–vascular endothelial growth factor
receptor (VEGF) agents, and as adjuvant therapy [59, 81,
82]. A recent phase III trial (EGF104900) showed a signif-
icantly longer PFS time with the combination of lapatinib
andtrastuzumabthanwithlapatinibalone(12weeksversus
8.1 weeks; p  .008; hazard ratio [HR], 0.73) in patients
withheavilypretreated,HER-2
MBCprogressingontras-
tuzumab[59].Asummaryofkeylapatinibcombinationtri-
als is presented in Table 3 [59, 80, 82–84].
Contrary to trastuzumab, lapatinib has activity against
CNS metastases in patients with HER-2
 breast cancer
[85–87]. These data suggest that, as a small molecule TKI,
it may be able to cross the blood–brain barrier to provide
effective therapeutic concentrations in cerebrospinal fluid
(unlike monoclonal antibodies such as trastuzumab).
Lapatinib appears to be associated with less cardiotox-
icitythantrastuzumab.Ananalysisof3,689patientstreated
with lapatinib in clinical trials reported a 1.6% incidence of
cardiac events, with most events being asymptomatic and
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Lapatinib Expanded Access Program, in which lapatinib
was given in combination with capecitabine to 2,500 pa-
tients with advanced breast cancer, reported a 0.6% inci-
dence of decreased left ventricular ejection fraction [89].
However, as lapatinib development is extended to include
the treatment of patients with lower-risk primary breast
cancer, it will be increasingly important to monitor cardio-
toxic effects. The most common adverse effects associated
with lapatinib treatment are gastrointestinal; lapatinib-
relateddiarrheagenerallyoccursearlyinthecourseoftreat-
ment, is mild to moderate, and does not require treatment,
although monitoring is important to identify patients who
may need intervention [90].
Erlotinib and Gefitinib. In the U.S. and Europe, erlotinib
monotherapy is currently approved for the treatment of pa-
tients with previously treated, locally advanced or meta-
static non-small cell lung cancer (NSCLC) or locally
advanced (U.S. only), unresectable (U.S. only) or meta-
static pancreatic cancer [91]. Gefitinib monotherapy is cur-
rently approved in the U.S. for the continued treatment of
NSCLC in patients who are benefiting or have benefited
fromtreatmentwithgefitinibafterfailureofbothplatinum-
based and docetaxel chemotherapies [92]; it has also now
been approved in Europe for use in NSCLC patients with
EGFR mutations, in all lines of therapy. Recent clinical
studies have not demonstrated any significant clinical ben-
efit for erlotinib or gefitinib either as single agents or in
combination with other agents in MBC [93–99]. Given
their lack of activity as monotherapy in MBC, studies con-
tinue to investigate the efficacy of erlotinib and gefitinib in
combination with other targeted therapies, chemotherapy,
or hormonal agents; however, tolerability issues may limit
this approach.
Neratinib. Neratinib (HKI-272) is an orally administered,
irreversible, pan-erbB kinase inhibitor [100]. The observa-
tionthatsomepatientswithchronicmyelogenousleukemia
were developing resistance to the TKI imatinib led to the
development of neratinib. In preclinical models, neratinib
has been shown to have promising antiproliferative activity
in both HER-2–dependent cell lines and tumor xenografts.
Clinical development has seen trials conducted in patients
with NSCLC and in patients with breast cancer. In a phase
I dose-escalation study in patients with solid tumors, the
maximum-tolerated dose was determined to be 320 mg/day
and the 240-mg/day dose was chosen for use in phase II
studies. A total of 25 patients in that study had MBC. Of
these, eight (32%) had a PR and one experienced SD for
24 weeks. Importantly, all responders were heavily pre-
treated, having received prior trastuzumab, anthracycline,
Table 3. Summary of key lapatinib combination trials
Trial Phase Patient characteristics
Treatment
regimen
Primary
endpoint ORR PFS/TTP Safety
[80] III HER-2
, locally
advanced breast cancer
or MBC refractory to
trastuzumab (n  324)
L  X
versus X
TTP 22% (L  X) versus
14% (X) (p  .09)
Median TTP, 8.4 mos
(L  X) versus 4.4
mos (X) (p  .001)
Adverse events and
cardiac events similar in
both groups
EGF104900
[59]
III Heavily pretreated MBC
(n  296)
L  T
versus L
PFS 10.3% (L  T)
versus 6.9% (L)
(p  .46)
Median PFS, 12.0
wks (L  T) versus
8.1 wks (L) (p 
.008; HR, 0.73; 27%
lower risk for
progression)
Manageable toxicity
VEG20007
[82, 83]
II HER-2
 MBC; cohort 1
(C1): P, 400 mg/day 
L, 1,000 mg/day or L,
1,500 mg/day (n  140);
C2: P, 800 mg/day  L,
1,500 mg/day or L, 1,500
mg/day (n  40)
L  PZ
versus L
RR C1: 12-wk RR, 36%
(L  PZ) versus
22% (L); PD, no
significant
difference. C2: TBD
C1: 12-wk PFS,
84.1% (L  PZ)
versus 63.2% (L)
(p  .009)
Manageable toxicity;
C1: diarrhea, rash, and
nausea; C2: diarrhea,
nausea, fatigue,
hypertension, and rash
[84] II HER-2
 advanced breast
cancer or MBC (n  52)
L  B PFS 13%; PR, 7; CBR
(CR  PR  SD
24 wks), 31%
12-wk PFS, 69% Generally well tolerated;
asymptomatic LVEF
decline, n  2, grade 2;
LVEF dysfunction, n 
3, one grade 2 and one
grade 1
Abbreviations: B, bevacizumab; CBR, clinical benefit rate; CR, complete response; G, grade; HER, human epidermal
growth factor receptor; HR, hazard ratio; L, lapatinib; LVEF, left ventricular ejection fraction; MBC, metastatic breast
cancer; ORR, objective response rate; PD, progressive disease; PFS, progression-free survival; PR, partial response; PZ,
pazopanib; RR, response rate; SD, stable disease; T, trastuzumab; TBD, to be determined; TTP, time to progression; X,
capecitabine.
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that neratinib has antitumor activity in patients with
HER-2
 MBC, either as a single agent in trastuzumab-
refractorypatientsorincombinationwithtrastuzumab,and
the safety profile of this agent has been manageable [102,
103].PhaseIIItrialsthatareongoingincludeastudyofsin-
gle-agent neratinib in trastuzumab-pretreated patients with
earlybreastcancer,astudyofneratinibversuslapatiniband
capecitabine in trastuzumab-pretreated MBC patients, and
a study of neratinib plus paclitaxel versus trastuzumab plus
paclitaxelasfirst-linetherapyforpatientswithMBC[104].
In summary, experience with agents targeting the HER
family shows that agents such as trastuzumab, lapatinib,
andneratinibareclinicallyactiveinMBCandaregenerally
well tolerated. However, evidence is increasing that agents
targeting HER-1 alone are not associated with clinical ben-
efitintheMBCsetting.Accuratepatientselectionbasedon
HER-2 overexpression is essential for trastuzumab-based
treatment and is likely to be important for other agents in
thisclass.However,identifyingsuitablepatientsmayprove
more difficult for TKIs, because receptor overexpression
alone does not seem to predict response to treatment [13].
HER-targeted agents may need to be used in combination
with chemotherapy to provide clinically relevant activity,
according to classical ORR criteria. Targeting HER-2 is as-
sociatedwithcardiactoxicity,whichisanespeciallyimpor-
tant consideration in the adjuvant setting and when
combininganti–HER-2agentswithcardiotoxicchemother-
apeutic drugs. Targeting HER-1 in combination with
HER-2, as with the TKIs lapatinib and neratinib, appears to
reduce the risk for cardiotoxicity, although the exact mech-
anisms underlying this observation remain unclear.
TARGETING DOWNSTREAM EFFECTOR MOLECULES
TargetingHERreceptorswithextracellularmonoclonalan-
tibodies and intracellular TKIs has shown promising clini-
cal activity. There is, however, a need for better treatment
of MBC patients because many of these current therapies
are restricted to a subset of the MBC patient population.
Targeting cellular signaling pathways, such as the MAPK
and PI3K pathways, downstream of HER receptors may be
an attractive avenue for novel treatments. Additionally,
there is some evidence that targeting heat shock proteins
(Hsps) and the apoptotic pathway may be viable options
for future therapeutic strategies in MBC. Recent devel-
opments in this field are briefly discussed in the follow-
ing sections.
MAPK and PI3K Signaling Pathway Overview
The MAPK pathway, also termed the extracellular signal-
regulated kinase (ERK) pathway, contains downstream ef-
fectorsoftheHERfamilyandothertyrosinekinases,andis
a central part of the signaling networks that control funda-
mental cellular processes, including cell proliferation, dif-
ferentiation, and survival [105] (Fig. 1). The PI3K pathway
alsoplaysacentralroleinnumerouscellularsignalingpath-
ways, and has been linked to a range of processes involved
in tumor development, including cell proliferation, cell
growth, cell motility, cell survival, and angiogenesis [24]
(Fig. 1).
Targeted Therapies Directed at the MAPK and PI3K
Signaling Pathways
The farnesyl transferase inhibitor tipifarnib (R115777) was
evaluated in phase III trials for the treatment of breast can-
cer,althoughfurtherdevelopmenthasnowbeenterminated
[106–108]. AZD6244 (ARRY-142886), an inhibitor of the
enzyme MEK, a component of the MAPK pathway, is cur-
rently in phase I clinical studies in several cancer types, in-
cluding breast cancer. Therapies targeting the PI3K
pathway include perifosine (KRX-0401), which inhibits
Akt phosphorylation [109], and the rapamycin analogs that
target mammalian target of rapamycin, such as temsiroli-
mus (CCl-779) [110–112] and everolimus (RAD001) [46,
47, 113, 114]. Recent data from two phase I trials suggest
that everolimus can help overcome resistance to trastu-
zumab in women with HER-2
 MBC. Everolimus plus
trastuzumab and weekly paclitaxel was shown to slow tu-
mor growth in 77% of patients, and the combination of
everolimus with trastuzumab and vinorelbine halted tumor
growth in 62% of patients [46, 47]. Although early indica-
tions suggest that targeting components of the PI3K path-
way may have some activity in the treatment of MBC,
additional data, including an understanding of combina-
tions and patient selection, are required.
Apoptosis Signaling Pathway Overview
Apoptosis, the process of programmed cell death, is gov-
erned by complex, gene-directed pathways [115–117].
Dysregulation of apoptosis plays a key role in tumorigene-
sisandcanallowtumorcellstobecomeresistanttoantican-
cer treatments [116, 117]. Rationale for targeting apoptosis
in the treatment of breast cancer includes the overexpres-
sion of the Bcl-2 protein in 40%–80% of human breast tu-
mors, which is associated with both resistance to
chemotherapy [118] and a better prognosis after chemo-
therapy [119]. Additionally, the association of Bcl-2 with
ER and/or PgR, loss of expression of the gene for the pro-
apoptotic protein Bax, and differential expression of tumor
necrosis factor–related apoptosis-inducing ligand-receptor
2 have all been correlated with prognosis in breast cancer
patients [118–121].
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Anticancer agents targeting the components of apoptotic
pathways are in the early stages of development, and no
agent specifically targeting apoptosis has yet been ap-
provedforuseincancertreatment.Arangeofapproachesis
being tested, including antisense DNA oligonucleotides
and antibody and small molecule inhibitors of the com-
ponents of apoptotic pathways. Few clinical data are cur-
rently available in breast cancer; however, preclinical studies
show that such agents do have anticancer activity, suggesting
thatthismaybeapromisingapproach,particularlywhenused
in combination with chemotherapy.
Hsp Signaling Pathway Overview
Hsp-90actsasaregulatoroftheHERfamilybyfunctioning
as a chaperone protein, binding to and maintaining client
molecules in their active conformation [122]. Hsp-90 is
overexpressed two- to tenfold in human tumor cells [122].
Although Hsp-90 is associated with many cellular path-
ways and effectors, both HER-1 and HER-2 require chap-
eroning by Hsp-90 for their stability [122], and Hsp-90 is
able to disrupt the ability of HER-2 to form signaling het-
erodimers on ligand binding [123].
Targeted Therapies Directed at the Hsp-90
Apoptotic Pathway
A range of Hsp-90 inhibitors has been developed and eval-
uated in clinical trials for the treatment of breast cancer, in-
cluding tanespimycin (KOS-953, 17-AAG in Cremophor).
Recent data from a phase II study of tanespimycin in com-
bination with trastuzumab as second-line therapy in pa-
tients with HER-2
 MBC showed evidence of good
antitumoractivity(CBR[PRSD4months],63%),and
the combination was very well tolerated [44]. Further stud-
ies are needed to confirm the effectiveness and safety pro-
file of current Hsp-90 inhibitors.
TARGETING THE ANGIOGENESIS PATHWAY
The process of angiogenesis (the formation of new blood ves-
sels from a pre-existing vascular bed) is complex and dy-
namic, and it is regulated by a range of pro- and
antiangiogenic molecules [124]. The VEGF and platelet-
derived growth factor (PDGF) families of proteins and their
receptors (VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-, and
PDGFR-) appear central to the process [124]. Activation of
VEGFRs and PDGFRs initiates signaling that results in nu-
merous cellular responses, including survival, mitogenesis,
migration, proliferation, and differentiation [124, 125]. Acti-
vation of the VEGF pathway also increases vascular perme-
ability and the movement of endothelial progenitor cells from
the bone marrow into the peripheral circulation [124].
Primary breast tumors express a variety of different an-
giogenic factors, with VEGF being the most abundant.
High VEGF expression appears to be correlated with poor
prognosis and response [126]. Levels of VEGF in breast
cancer tumors are a prognostic factor for relapse-free and
overall survival in patients with both lymph node–negative
and lymph node–positive disease [127, 128], and they pre-
dict response to both tamoxifen and chemotherapy in ad-
vanced disease [129]. Similarly, a proportion of invasive
breast cancers that overexpress PDGFR- have been asso-
ciated with greater biological aggressiveness and a higher
likelihood of lymph node metastasis [130].
It is increasingly being accepted that tumor cell prolif-
eration alone is insufficient to result in a substantial tumor
mass. Angiogenesis is essential for tumors to develop into
detectable localized masses, and for metastasis to occur [131,
132]. Given their central roles in tumor angiogenesis and
growth, the VEGF and PDGF signaling pathways are key tar-
getsforbreastcancertherapy.However,withconsiderablere-
dundancy in angiogenic signaling pathways, the inhibition of
more than one receptor is likely necessary to block angiogen-
esis.Ithasbeenhypothesizedthatanti-VEGFagentsmaypre-
vent the development of new tumor vasculature and induce
normalization of existing, inefficient tumor vasculature (re-
sulting from overexpression of VEGF) [133]. These agents,
then, may allow better delivery of cytotoxic therapies to the
tumor, suggesting a potential role for anti-VEGF therapy in
conjunction with chemotherapy [133, 134].
Targeted Therapies Directed at Angiogenesis
Several therapies targeting angiogenesis are in develop-
ment for breast cancer. These include monoclonal antibod-
ies that act extracellularly by binding to receptors or their
ligands, such as bevacizumab (Avastin; Genentech, Inc.,
SouthSanFrancisco,CA),andTKIsthatactintracellularly,
such as sunitinib (Sutent; Pfizer, Inc., New York) (Table
1). Bevacizumab is an anti-VEGF humanized monoclonal
antibody administered as an i.v. infusion. It acts by binding
to all VEGF isoforms, thus removing VEGF from the cir-
culation and preventing activation of VEGFRs [135]. Bev-
acizumab is currently approved for use in combination with
paclitaxel as first-line treatment for patients with MBC [136].
Anumberofsingle-agentTKIswithmultiplemolecular
targets have been developed as an alternative to combining
multiple agents. These were developed based on previous
studies showing that combining agents that target different
pathwaysmayhavesynergisticactivityanddelayorreverse
resistance [59, 137–139]. A range of oral, antiangiogenic
TKIs with multiple targets is currently in development for
MBC. These include sunitinib, pazopanib, sorafenib (Nex-
avar; Bayer Pharmaceuticals Corporation, West Haven,
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ceptor tyrosine kinases (VEGFR-1, VEGFR-2, VEGFR-3,
PDGFR-, PDGFR-, Kit, REarranged during Transfec-
tion, FMS-like tyrosine kinase [FLT]-3, and colony-stimu-
lating factor 1 receptor) [140–145]. It has antiangiogenic
andantitumoractivitiesandisapprovedmultinationallyfor
the treatment of advanced renal cell carcinoma (RCC) and
for gastrointestinal stromal tumors after disease progres-
sion on or intolerance to imatinib mesylate therapy [146].
Pazopanib targets VEGFR, PDGFR, and Kit and is cur-
rently in development in a number of tumor types, includ-
ing breast cancer. Although originally developed as a Raf
inhibitor, sorafenib also inhibits the activity of VEGFR-2
and VEGFR-3, PDGFR-, FLT-3, and Kit; thus, it may in-
hibit tumor growth both directly (through Raf and Kit) and
indirectly,throughinhibitionofangiogenesis[147,148].In
both the U.S. and Europe, sorafenib is currently indicated
forthetreatmentofpatientswithadvancedRCCandforthe
treatment of unresectable hepatocellular carcinoma [149].
Axitinib inhibits all known VEGFRs, in addition to
PDGFR- and the stem cell factor receptor Kit, and is cur-
rently being investigated in a range of tumor types, includ-
ing breast cancer.
Extracellular Targeted Therapies:
Monoclonal Antibodies
Bevacizumab. Phase III studies have investigated bevaci-
zumab combined with chemotherapy (Table 4) [150–153]. In
2008, the U.S. Food and Drug Administration (FDA) ap-
proved bevacizumab in combination with paclitaxel for the
first-line treatment of locally recurrent breast cancer or MBC
[136]. This approval was controversial after the FDA’s Onco-
logic Drugs Advisory Committee recommended that the
phase III data (E2100) were insufficient to establish a favor-
able risk–benefit profile, with the efficacy data based on PFS
rather than overall survival. The E2100 study reported a 52%
lower risk for disease progression or death with bevacizumab
incombinationwithpaclitaxelthanwithpaclitaxelaloneanda
doubling of the PFS time (paclitaxel alone, 5.8 months; com-
bination, 11.3 months; HR, 0.48; p  .0001) [151].
ResultsfromthephaseIIIAVADOtrialdemonstratedthat
bevacizumab (7.5 mg/kg or 15 mg/kg once every 3 weeks)
combinedwithdocetaxelresultedinasignificantlylongerPFS
time (the primary endpoint) than docetaxel alone (8.7 months
versus 8.8 months versus 8.0 months for the low- and high-
dose combination arms versus docetaxel alone) [152], al-
though the treatment effect was not as robust as in the E2100
study.BasedontheresultsfromtheAVADOtrial,theexisting
EU label permitting the use of bevacizumab in combination
withdocetaxelwasextendedtoallowbevacizumabtobecom-
bined with docetaxel, thus allowing additional patients access
to bevacizumab treatment. Further analyses of the AVADO
trial have revealed that treatment continuation with single-
agent bevacizumab after discontinuation of docetaxel appears
to delay disease progression [154], that there is no apparent
correlation between the efficacy of bevacizumab plus do-
cetaxel and hypertension or G-CSF use [155], and that the
combination does not appear to be associated with a higher
incidence of grade 3–5 bleeding events [156].
Table 4. Summary of key bevacizumab trials
Trial Phase
Patient
characteristics
Treatment
regimen
Primary
endpoint ORR PFS/TTP OS Safety
E2100
[151]
III MBC, previously
untreated (n 
722)
B  PX versus PX PFS ORR, 36.9% (B 
PX) versus 21.2%
(PX) (p  .001)
PFS, 11.8 mos
(B  PX) versus
5.9 mos (PX)
(p  .001)
OS, 26.7 mos (B 
PX) versus 25.2
mos (PX) (p  .16)
Grade 3 or 4
hypertension was
more frequent in
B  PX arm
AVADO
[152]
III MBC, previously
untreated (n 
736)
B (low dose  high
dose)  D versus D
PFS ORR, 55% (B  D
low) versus 63%
(B  D high)
versus 44% (D)
PFS, 8.7 mos (B 
D low) versus 8.8
mos (B  D high)
versus 8.0 mos (D)
OS, NS No difference in
grades 3–5 bleeding
events
[150] III MBC patients with
prior therapy with
both an A and a T
(n  462)
B  X versus X
alone
OS ORR, 19.8% (B 
X) versus 9.1%
(X) (p  .001)
PFS, NS OS, NS Well tolerated, more
grade 3 or 4
hypertension with
B  X than with X
[153] III MBC (or locally
recurrent breast
cancer), previously
untreated patients
B  chemotherapy
( Xo rTo rA )
versus placebo 
chemotherapy (X or
To rA )
PFS ORR, 35.4% (B 
X) versus 23.6%
(placebo  X)
(p  .0097); ORR
51.3% (B  T/A)
versus 37.9%
(placebo  T/A)
(p  .0054)
PFS, 8.6 mos (B 
X) versus 5.7 mos
(placebo  X) (p 
.0002); PFS 9.2
mos (B  T/A)
versus 8.0 mos
(placebo  T/A)
(p .0001)
OS, 29.0 mos (B 
X) versus 21.2 mos
(placebo  X)
(p  .27); OS 25.2
mos (B  T/A)
versus 23.8 mos
(placebo  T/A)
(p  .83)
Safety consistent
with prior studies.
No new signals seen
in either
chemotherapy group
Abbreviations: A, anthracycline; B, bevacizumab; D, docetaxel; G, grade; MBC, metastatic breast cancer; NS, not
significant; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PX, paclitaxel; T, taxane;
TTP, time to progression; X, capecitabine.
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ity as a single agent in MBC patients, combination therapy
with chemotherapeutic agents has been associated with clini-
calactivityinthispatientpopulation.ThissuggeststhatVEGF
inhibition combined with chemotherapy is a promising treat-
ment strategy in this setting. Further studies are under way to
explore the use of bevacizumab with different chemothera-
peuticregimens,hormonaltreatments,andothertargetedther-
apies (including lapatinib and trastuzumab) in patients with
MBC. Additionally, trials of bevacizumab are ongoing in the
adjuvant and neoadjuvant settings, and preliminary reports
suggest that this approach may be feasible; however, there are
concerns about hypertension and bleeding [157]. Indeed, hy-
pertension, bleeding, and thrombosis remain potential safety
concerns with a number of anti-VEGF therapies, and this area
requiresfurtherstudy.Futuretrialsshouldfocusonidentifying
those patients who will derive the most benefit from bevaci-
zumab-basedregimensandhowbesttocombinebevacizumab
with other cancer therapies (which therapies should be com-
bined and whether sequential or concurrent administration is
most effective). Overall, growing clinical experience with
agents targeting angiogenic processes, such as bevacizumab,
hasprovidedproofofconceptfortheuseofthesetreatmentsin
MBC patients.
Intracellular Targeted Therapies: TKIs
Sunitinib. Sunitinib has been shown to have antitumor ac-
tivity in breast cancer preclinical studies, both as a single
agent and in combination with chemotherapy [140, 143,
145]. Data from a phase II study of sunitinib monotherapy
in patients with refractory MBC reported single-agent ac-
tivityinheavilypretreatedpatients(n64),previouslyex-
posedtoananthracyclineandataxane[158].TheORRwas
11%, with a median TTP of 10 weeks, and toxicities were
manageable [158]. Studies and case series evaluating
sunitinib given in combination with taxane therapy for
MBC have reported antitumor activity and a manageable
and tolerable safety profile [159–161]. Briefly, sunitinib
plus paclitaxel (n  20) was generally well tolerated and
showed preliminary evidence of clinical activity, with an
ORR of 38.9% [159]. Sunitinib given sequentially with do-
cetaxel (n  22) also showed activity and a manageable
safety profile [160, 161]. Of 18 evaluable patients in an ex-
ploratorystudy,72.2%hadPRsand27.7%hadSD[160].In
patients with HER-2
 MBC, sunitinib combined with tras-
tuzumab was tolerable and associated with a preliminary
ORR of 24% (n  51) [162]. A triple combination of
sunitinib, trastuzumab, and docetaxel was also found to be
clinicallyfeasibleinHER-2
MBCpatients,withaprelim-
inary ORR of 77.7% (n  18) [163].
PhaseIIItrialsofsunitinibincombinationwithavariety
of cytotoxic agents are under way in first- and second-line
MBC therapy [164]. Although two phase III studies of
sunitinib in the advanced disease setting (single-agent
sunitinib in the first, second, and third lines of therapy and
first-line sunitinib plus paclitaxel versus bevacizumab plus
paclitaxel) have been stopped after preplanned interim analy-
ses indicated that the primary endpoint would not be reached,
other combination phase III studies are ongoing. These in-
cludeSUN1099(second-andthird-linesunitinibpluscapecit-
abine) and SUN1064 (first-line sunitinib plus docetaxel).
Additionally, a phase II study is evaluating second-line
sunitinib versus standard of care in previously treated ad-
vanced triple-negative breast cancer (SUN 1077) [104].
Pazopanib. Results of a phase II study (VEG20007) eval-
uating combination therapy with pazopanib and lapatinib
versus lapatinib alone described superior activity with the
combination of the two small molecule TKIs, pazopanib
plus lapatinib versus lapatinib alone, in HER-2
 patients
(n  140) (Table 3) [82]. At the interim analysis, the re-
sponse rate (independent assessment) was higher for the
combination (36%; n  32) than for lapatinib monotherapy
(22%; n  30), whereas there was no significant difference
intherateofprogressivedisease[82].Thisisthefirstphase
II trial to demonstrate the clinical activity of TKIs (in the
absence of chemotherapy) in the first-line treatment of
MBC patients. However, because of the small sample size,
heterogeneous population, and some missing efficacy data
(15%–20%ofpatientsinbothgroups),thesecanbeconsid-
ered preliminary data only.
Sorafenib. Sorafenib inhibited MAPK activity in breast
cancer cell lines expressing mutations of K-Ras or B-Raf,
and showed antitumor and antiangiogenic activity in a hu-
man breast cancer xenograft model [148]. Data from a
phase II study in patients with MBC (n  23) previously
exposed to an anthracycline and/or a taxane showed no sig-
nificant clinical activity with sorafenib (6-month OS rate,
81%; 2-month PFS rate, 53%; 4-month PFS rate, 24%;
6-month PFS rate, 6%) [165]. Single-agent treatment was
well tolerated in that study; however, significant and sus-
tained increases in blood pressure were reported in a study
of sorafenib monotherapy in patients with metastatic solid
tumors [165, 166]. Current data suggest little activity for
sorafenib as a single agent in MBC patients; ongoing stud-
iesareexploringcombinationtreatmentwithpaclitaxeland
with anastrozole in MBC.
Axitinib. In preclinical studies, axitinib was shown to se-
lectively block VEGF-stimulated receptor phosphorylation
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eration and survival, and in a human breast cancer xeno-
graft model it significantly inhibited tumor growth and
disrupted tumor microvasculature as assessed by dynamic
contrast-enhanced magnetic resonance imaging [167]. A
randomized,double-blindphaseIIstudyofaxitinibincom-
bination with docetaxel versus docetaxel as first-line ther-
apy for patients with MBC (n  168) has shown that this
regimen has promising antitumor activity [168]. In the
overall patient population (n  168), the TTP was 8.2
monthsforpatientsinthecombinationarmversus7months
for patients treated with docetaxel alone (p  .052) and the
ORRwas40%forpatientsinthecombinationarmversus23%
for those given docetaxel alone (p.038). In a prior adjuvant
chemotherapysubgroup(n92),theTTPwas9.0monthsfor
axitinib plus docetaxel versus 6.3 months for docetaxel alone
(p  .012) and the ORR was 45% for axitinib plus docetaxel
versus 13% for docetaxel alone (p  .003) [168]. The treat-
menthadanacceptablesafetyprofilethatwassimilartothatof
other multitargeted agents [168]. Grade 3 or 4 adverse events
that occurred at a higher rate with axitinib plus docetaxel than
withdocetaxelaloneincludedfebrileneutropenia,fatigue,sto-
matitis, diarrhea, and hypertension [168].
Todate,themultitargetedTKIsdiscussedhavenotbeen
validated in phase III trials in MBC patients, although there
is preliminary evidence of clinical activity. Of the four
agentsdescribedabove,three(pazopanib,sunitinib,andax-
itinib) appear to have the most clinical activity to date.
Based on experience with other targeted agents in breast
cancer, and with these TKIs in other indications, combina-
tions will hopefully show greater efficacy in the treatment
of MBC. Current trials of multitargeted TKIs in MBC pa-
tients are summarized in Table 5.
CONCLUSIONS
In recent years, research efforts have focused on the signal-
ing pathways involved in the growth and survival of breast
cancer cells, leading to the development of a range of tar-
geted agents with promising clinical activity. The encour-
agingsuccessoftrastuzumab,basedontheidentificationof
HER-2 as a molecular target, has provided the rationale for
studying the array of targeted agents currently in clinical
development for MBC. The various extracellular and intra-
cellular targets of breast cancer therapies discussed in this
review are presented in Fig. 3.
The lapatinib data have shown that other means of HER
family targeting are effective, although the lack of success
with erlotinib and gefitinib underlines the importance of
careful evaluation of these agents. Ongoing research must
define how and when to use trastuzumab and lapatinib in
the various treatment lines for MBC. Numerous therapies
that target intracellular signaling molecules are in develop-
ment,andearlyevidencesuggeststhatsomeoftheseagents
(everolimus and tanespimycin) may have clinical utility in
Table 5. Key trials of antiangiogenic TKIs in MBC patients, recruiting as of June 2009
Drug
Trial
identifier Phase
Patient
characteristics
Expected n
of patients
enrolled Treatment regimen
Line of
therapy
Primary
endpoint
Sunitinib NCT00435409
(SUN 1099)
III ABC 430 SU  X versus X Second line PFS
NCT00393939
(SUN 1064)
III ABC 550 SU  D versus D First line PFS
NCT00246571
(SUN 1077)
II ABC triple
negative
200 SU versus standard of
care chemotherapy
Second line PFS
Pazopanib NCT00509587 II MBC 35 PZ versus PL Second line ORR
Sorafenib NCT00632541 II MBC 43 SB  B Second line PFS
NCT00499525 IIB MBC 180 SB  PX versus PX First line PFS
NCT00622466 II MBC 41 SB  PX First line ORR
NCT00217399 I/II MBC 50 SB  A Second line CBR
NCT00722072 II MBC 43 SB  F Second line PFS
NCT00493636 II MBC 220 SB versus PL First or Second
line
PFS
Abbreviations: A, anastrozole; ABC, advanced breast cancer; B, bevacizumab; CBR, clinical benefit rate; D, docetaxel; DR,
duration of response; F, fulvestrant; MBC, metastatic breast cancer; ORR, objective response rate; OS, overall survival;
PFS, progression-free survival; PL, placebo; PX, paclitaxel; PZ, pazopanib; SB, sorafenib; SU, sunitinib; TKI, tyrosine
kinase inhibitor; Triple negative, estrogen receptor negative, progesterone receptor negative, and human epidermal growth
factor receptor 2 negative; X, capecitabine.
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benefitinthispatientpopulation,withtheanti-VEGFantibody
bevacizumab already licensed in combination with chemo-
therapy. Therapies targeting multiple receptors, including
sunitinib and pazopanib, are also demonstrating clinical activ-
ity in early trials. It is anticipated that combining these treat-
ments with other targeted agents and/or chemotherapy may
offeraneffectiveapproachtothefuturetreatmentofMBCpa-
tients, but combinations of the targeted agents must be evalu-
ated carefully for acceptable toxicity profiles.
Novel targeted therapies offer an attractive approach to
the future treatment of MBC patients, with the prospect of
individualizedtherapybasedonthegeneticexpressionpro-
files or clinical characteristics of individual patient’s tu-
mors. However, despite recent advances, there are many
unanswered questions regarding the optimal treatment and
long-termmanagementofMBCpatientswithtargetedagents.
Future studies will need to address how best to incorporate
theseagentsintoexistingtreatmentregimens,toidentifythose
patient subgroups likely to derive most benefit from a given
therapy, and to determine when and in which combinations
targeted therapy should be administered.
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